Calcium Channel Autoantibodies Predicted Sudden Cardiac Death and All-Cause Mortality in Patients with Ischemic and Nonischemic Chronic Heart Failure
Table 1
Clinical data of control subjects and patients with CHF.
Clinical characteristic
Control (834)
CHF
DCM ()
ICM ()
Male, (%)
449 (53.84%)
558 (76.23%)
<0.001
885 (80.53%)
<0.001
Age (y)
=0.052
<0.001
BMI
=0.587
=0.453
NYHA class, (%)
I
834 (100%)
0
—
0
—
II
0
157 (21.45%)
—
582 (52.96%)
—
III
0
306 (41.80%)
—
338 (30.76%)
—
IV
0
269 (36.75%)
—
179 (16.28%)
—
Hypertension, (%)
199 (23.86%)
242 (33.06%)
=0.003
672 (61.15%)
<0.001
Hyperlipidemia, (%)
53 (6.35%)
76 (10.38%)
<0.001
329 (29.94%)
<0.001
Diabetes mellitus, (%)
60 (7.19%)
120 (16.39%)
<0.001
317 (28.84%)
<0.001
ECG and arrhythmias
MHR (beats/min)
<0.001
<0.001
AF ()
0
177 (24.18%)
—
130 (11.83%)
—
PVC ()
0
192 (26.23%)
—
217 (19.75%)
—
QTc (ms)
<0.001
<0.001
QRS duration (ms)
<0.001
<0.001
Hemodynamic parameters
LVEF (%)
<0.001
<0.001
LVEDD (mm)
<0.001
<0.001
Medications for CHF
ACEI, (%)
0
437 (59.69%)
—
710 (64.60%)
—
Diuretic, (%)
0
565 (77.18%)
—
741 (67.42%)
—
Digoxin, (%)
0
483 (65.98%)
—
697 (63.42%)
—
-blocker, (%)
0
570 (77.87%)
—
776 (70.61%)
—
CCBs, (%)
0
24 (3.28%)
—
248 (22.57%)
—
ICD, (%)
0
10 (1.37%)
—
28 (2.55%)
—
Values are mean ± SD or number (%). was considered significant compared with the control group. Premature vascular contraction (PVC) indicated >3000 beats/24 h. AF: atrial fibrillation; ACEI: angiotensin-converting enzyme inhibitor; BMI: body mass index; CHF: chronic heart failure; NYHA: New York Heart Association; DCM: dilated cardiomyopathy; ICM: ischaemic cardiomyopathy; LVEDD: left ventricular end-diastolic diameter; LVEF: left ventricular ejection fraction; MHR: mean heart rate; ICD: implantable cardioverter defibrillator; SCD: sudden cardiac death.